Investors & News — Mezzion

LATEST NEWS

Mezzion Pharma Completes FUEL-2 Phase 3 Regulatory Milestone

LATEST NEWS

Mezzion Secures Strategic Financing to Support Advancement of Global Phase 3 FUEL-2 Trial in Fontan Patients

LATEST NEWS

Mezzion Reports Pre-IND FDA Feedback on the Development of Udenafil in ADPKD

News

Featured

Mezzion Pharma Completes FUEL-2 Phase 3 Regulatory Milestone

June 20, 2026

Mezzion Pharma Completes FUEL-2 Phase 3 Regulatory Milestone

June 20, 2026

Read more →

June 20, 2026

Mezzion Secures Strategic Financing to Support Advancement of Global Phase 3 FUEL-2 Trial in Fontan Patients

June 20, 2026

Mezzion Secures Strategic Financing to Support Advancement of Global Phase 3 FUEL-2 Trial in Fontan Patients

June 20, 2026

Read more →

June 20, 2026

Mezzion Reports Pre-IND FDA Feedback on the Development of Udenafil in ADPKD

June 20, 2026

Mezzion Reports Pre-IND FDA Feedback on the Development of Udenafil in ADPKD

June 20, 2026

Read more →

June 20, 2026

New ICD-10 Codes Recognize Fontan-Associated Conditions, Advancing Care and Coverage for Rare Congenital Heart Disease Community - PR Newswire

April 16, 2025

New ICD-10 Codes Recognize Fontan-Associated Conditions, Advancing Care and Coverage for Rare Congenital Heart Disease Community - PR Newswire

April 16, 2025

Read more →

April 16, 2025

The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation - ScienceDirect

December 26, 2023

The Effect of Udenafil on Heart Rate and Blood Pressure in Adolescents With the Fontan Circulation - ScienceDirect

December 26, 2023

Read more →

December 26, 2023

Mezzion Pharma Raises Nearly $40M to Advance a First-to-Market Treatment Option for Fontan Patients - PR Newswire

April 24, 2023

Mezzion Pharma Raises Nearly $40M to Advance a First-to-Market Treatment Option for Fontan Patients - PR Newswire

April 24, 2023

Read more →

April 24, 2023

Mezzion Pharma Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects - PR Newswire

February 20, 2023

Mezzion Pharma Submits Protocol for Confirmatory Pivotal Phase 3 Trial ("FUEL-2") in Fontan Subjects - PR Newswire

February 20, 2023

Read more →

February 20, 2023

Mezzion Pharma Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease - PR Newswire

May 30, 2022

Mezzion Pharma Receives Clear FDA Path Forward for the Approval of Udenafil for Single Ventricle Heart Disease - PR Newswire

May 30, 2022

Read more →

May 30, 2022